Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid

Digestive and Liver Disease

Volumn 41, Issue 5, 2009, Pages 328-337

  Kim, Y H ^a   Kim, M H ^a   Kim, B J ^a   Kim, J J ^a   Chang, D K ^a   Son, H J ^a   Rhee, P L ^a   Rhee, J C ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

5 Aminosalicylic acid; cDNA microarray; Colon cancer; Matrix metalloproteinase; NF B

Indexed keywords

COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESALAZINE; METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION; HT29 CELLS; HUMANS; MESALAMINE; METALLOPROTEASES; NEOPLASM INVASIVENESS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 63049083707     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.09.003     Document Type: Article

References (46)

1. Choi P.M., and Zelig M.P. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35 (1994) 950-954
2. Lippman S.M., Benner S.E., and Hong W.K. Chemoprevention. Strategies for the control of cancer. Cancer 72 (1993) 984-990
3. Janne P.A., and Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 342 (2000) 1960-1968
4. Drazen J.M. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med 352 (2005) 1131-1132
5. Kamm M.A. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 16 Suppl. 4 (2002) 21-24
6. Das K.M., Chowdhury J.R., Zapp B., and Fara J.W. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 77 (1979) 280-284
7. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
8. Narisawa T., and Fukaura Y. Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. Dis Colon Rectum 46 (2003) 900-903
9. MacGregor D.J., Kim Y.S., Sleisenger M.H., and Johnson L.K. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+mouse. Int J Oncol 17 (2000) 173-179
10. Dolcet X., Llobet D., Pallares J., and Matias-Guiu X. NF-κB in development and progression of human cancer. Virchows Arch 446 (2005) 475-482
11. Kwaan H.C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11 (1992) 291-311
12. Stetler-Stevenson W.G., Hewitt R., and Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7 (1996) 147-154
13. Das R., Mahabeleshwar G.H., and Kundu G.C. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278 (2003) 28593-28606
14. Mori N., Sato H., Hayashibara T., Senba M., Geleziunas R., Wada A., et al. Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor kappaB. Gastroenterology 124 (2003) 983-992
15. Shukla S., MacLennan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I., et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6 (2004) 390-400
16. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., and Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5 (1999) 119-127
17. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100 (1997) 2952-2960
18. Sasaki N., Morisaki T., Hashizume K., Yao T., Tsuneyoshi M., Noshiro H., et al. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7 (2001) 4136-4142
19. Dignam J.D. Preparation of extracts from higher eukaryotes. Methods Enzymol 182 (1990) 194-203
20. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., and Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56 (1996) 190-196
21. Pinczowski D., Ekbom A., Baron J., Yuen J., and Adami H.O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107 (1994) 117-120
22. Eaden J., Abrams K., Ekbom A., Jackson E., and Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14 (2000) 145-153
23. Moody G.A., Jayanthi V., Probert C.S., Mac Kay H., and Mayberry J.F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8 (1996) 1179-1183
24. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., and Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95 (2000) 3452-3457
25. Egan L.J., Mays D.C., Huntoon C.J., Bell M.P., Pike M.G., Sandborn W.J., et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274 (1999) 26448-26453
26. Kaiser G.C., Yan F., and Polk D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 116 (1999) 602-609
27. Weber C.K., Liptay S., Wirth T., Adler G., and Schmid R.M. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119 (2000) 1209-1218
28. Shao J., Fujiwara T., Kadowaki Y., Fukazawa T., Waku T., Itoshima T., et al. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19 (2000) 726-736
29. Okayasu I., Ohkusa T., Kajiura K., Kanno J., and Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39 (1996) 87-92
30. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
31. Li Q., Withoff S., and Verma I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 26 (2005) 318-325
32. Yao M., Lam E.C., Kelly C.R., Zhou W., and Wolfe M.M. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 90 (2004) 712-719
33. Sato H., Kida Y., Mai M., Endo Y., Sasaki T., Tanaka J., et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7 (1992) 77-83
34. Niu J., Gu X., Turton J., Meldrum C., Howard E.W., and Agrez M. Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun 249 (1998) 287-291
35. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., and Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 31 (1990) 1271-1276
36. Shah S., and Forbes D.J. Separate nuclear import pathways converge on the nucleoporin Nup153 and can be dissected with dominant-negative inhibitors. Curr Biol 8 (1998) 1376-1386
37. Nakielny S., Shaikh S., Burke B., and Dreyfuss G. Nup153 is an M9-containing mobile nucleoporin with a novel Ran-binding domain. EMBO J 18 (1999) 1982-1995
38. Toyoda H., Komurasaki T., Ikeda Y., Yoshimoto M., and Morimoto S. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 377 (1995) 403-407
39. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
40. Shirakata Y., Komurasaki T., Toyoda H., Hanakawa Y., Yamasaki K., Tokumaru S., et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 275 (2000) 5748-5753
41. Taylor D.S., Cheng X., Pawlowski J.E., Wallace A.R., Ferrer P., and Molloy C.J. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 96 (1999) 1633-1638
42. Radinsky R., Risin S., Fan D., Dong Z., Bielenberg D., Bucana C.D., et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1 (1995) 19-31
43. Roberts R.B., Min L., Washington M.K., Olsen S.J., Settle S.H., Coffey R.J., et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99 (2002) 1521-1526
44. Zeng H., Sanyal S., and Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276 (2001) 32714-32719
45. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 (2001) 575-583
46. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.C., Wang G.G., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439 (2006) 204-207